Published in Blood Weekly, July 17th, 2003
Researchers in California "assessed the effect of rabbit antithymocyte globulin manufactured by Fresenius (ATG-F) on the hemostatic system in patients (n = 12) with various hematological malignancies undergoing hematopoietic stem cell transplantation (HSCT) from HLA-matched unrelated donors."
"For this purpose," M. Weber and coauthors at Scripps Research Institute in La Jolla "monitored different parameters of coagulation before, during and after the administration of ATG-F."
"As a control group, we recruited patients (n = 10) undergoing HSCT from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.